• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BD to put $1.2B into drug-delivery plant expansions

December 2, 2020 By Sean Whooley

Becton Dickinson (NYSE:BDX) announced today that it plans to invest $1.2 billion to expand and upgrade multiple drug-delivery facilities.

Franklin Lakes, N.J.-based BD plans to invest the $1.2 billion over a four-year period to expand and upgrade manufacturing capacity and technology for pre-fillable syringes (PFS) and advanced drug-delivery systems (ADDS) across its six global manufacturing locations, while adding another manufacturing facility in Europe, according to a news release.

Becton Dickinson’s six manufacturing facilities for its pharmaceutical systems include locations in Columbus, Nebraska; Cuautitlán, Mexico; Fukushima, Japan; Le Pont-de-Claix, France; Swindon, United Kingdom; and Tatabánya, Hungary.

The company anticipates that the Europe facility will be operational by the end of 2023. In addition to the new plant, the investment is earmarked for expansion, new product innovations, manufacturing technology enhancements and business continuity improvements.

BD has commitments for over 800 million needles and syringes to deliver future COVID-19 vaccines in the U.S., UK, Canada and elsewhere — a $100 million to $150 million opportunity.

“BD invented the ready-to-fill pre-fillable syringe technology, and today’s announcement demonstrates our continued commitment to better serve our customers,” BD Pharmaceutical Systems worldwide president Eric Borin said in the release. “Since 2018, BD has added 350 million units of manufacturing capacity for glass barrel pre-fillable syringes, and this new commitment will invest in additional upgrades at all of our Pharmaceutical Systems manufacturing facilities and across multiple product categories.

“In addition, this investment positions BD to have the needed surge capacity for increased pre-fillable syringe demand during times of pandemic response or periods of significant growth of new injectable drugs and vaccines. This significant investment in one of BD’s fastest-growing business units will further advance our leadership position and enable continued strong growth in the years ahead.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Becton Dickinson

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS